Vireo Growth (VREOF) Net Cash Flow (QoQ) (2020 - 2026)
Vireo Growth (VREOF) Net Cash Flow (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | Vireo Growth | 491.44 Mn | 349.14 Mn | 95.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 208.74% |
| Dec 31, 2025 | -56.34% |
| Sep 30, 2025 | -43.21% |
| Jun 30, 2025 | 470.08% |
| Mar 31, 2025 | -106.40% |
| Dec 31, 2024 | 2,235.12% |
| Sep 30, 2024 | -187.31% |
| Jun 30, 2024 | 59.10% |
| Mar 31, 2024 | -225.94% |
| Dec 31, 2023 | 36.84% |
| Sep 30, 2023 | 94.92% |
| Jun 30, 2023 | 120.83% |
| Mar 31, 2023 | 28.22% |
| Dec 31, 2022 | -237.39% |
| Sep 30, 2022 | -41.80% |
| Jun 30, 2022 | 227.70% |
| Mar 31, 2022 | -294.14% |
| Dec 31, 2021 | 137.32% |
| Sep 30, 2021 | 54.16% |
| Jun 30, 2021 | -246.67% |